Phase I trial of etirinotecan pegol [NKTR 102] in combination with fluorouracil in patients with refractory solid tumours.

Trial Profile

Phase I trial of etirinotecan pegol [NKTR 102] in combination with fluorouracil in patients with refractory solid tumours.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2014

At a glance

  • Drugs Etirinotecan pegol (Primary) ; Fluorouracil; Folinic acid
  • Indications Advanced breast cancer; Colorectal cancer; Gallbladder cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Phaeochromocytoma; Sarcoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Nektar Therapeutics
  • Most Recent Events

    • 23 Apr 2014 Status changed from recruiting to active, no longer recruiting.
    • 28 Jun 2010 New trial record
    • 24 Jun 2010 The first patients have been dosed, according to a Nektar Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top